BioSpace News Archive

Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced financial results for the quarter ended June 30, 2022.

Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today reported its financial and operating results for the second quarter ended June 30, 2022 and provided an update on its full year 2022 financial guidance and recent corporate activities.

Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the second quarter ended June 30, 2022, and provided a business update.

Agiliti Inc., a nationwide provider of healthcare technology management and service solutions to the United States healthcare industry, announced its financial results for the quarter ended June 30, 2022, and reaffirmed its full-year financial guidance with results expected at the lower end of its range.

Certara, Inc., a global leader in biosimulation, reported its financial results for the second quarter of fiscal year 2022 and adjusted its full year guidance.

ClearPoint Neuro, Inc., a global therapy-enabling platform company providing navigation and delivery to the brain, announced financial results for its second quarter ended June 30, 2022.

Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the second quarter ended June 30, 2022.

Heron Therapeutics, Inc. today announced financial results for the three and six months ended June 30, 2022 and highlighted recent corporate updates.

IceCure Medical Ltd. today announced it will report its business and financial results as of and for the six months ended June 30, 2022 on Monday, August 15, 2022 with a press release issued at 4:00 p.m. EDT and will conduct a conference call that will take place that day at 4:30 p.m. EDT.

CytRx Corporation welcomes Mr. Cary J. Claiborne to the CytRx Board of Directors (the “Board”).